Table 2.

Risk of breast cancer-specific death in 584 Nordic carriers of BRCA2 mutations according to key tumour characteristics, oophorectomy and treatment.

		Univariate disease-specific survival		Multivariatea disease-specific survival
		HR (95% CI)	P value	HR (95% CI)	P value
Year of diagnosis	Continuous	0.96 (0.94–0.98)	<0.001	0.98 (0.95–1.01)	0.16
Size >20–≤50 vs ≤20 mm	244 vs 311	1.73 (1.23–2.45)	<0.01	1.57 (1.07–2.32)	0.02
>50 vs ≤20 mm	29 vs 311	2.78 (1.49–5.19)	<0.01	2.65 (1.32–5.34)	0.01
Lymph node status (pos/neg)	314 vs 270	1.49 (1.06–2.09)	0.02	1.65 (1.04–2.62)	0.03
Grade 2 + 3 vs 1	472 vs 61	0.65 (0.40–1.05)	0.08	0.71 (0.43–1.16)	0.17
ER+ 0–5 y vs ER− b	354 vs 126	0.42 (0.23–0.77)	<0.01	0.49 (0.26–0.93)	0.03
ER + 5+ y vs ER− c	377 vs 126	1.60 (0.94–2.74)	0.09	1.91 (1.07–3.39)	0.03
Oophorectomyd	176 vs 408	0.39 (0.24–0.64)	<0.001	0.67 (0.38–1.20)	0.18
Mastectomy vs lumpectomy	369 vs 215	1.34 (0.92–1.93)	0.12	0.94 (0.59–1.51)	0.81
Adjuvant chemotherapy, any	383 vs 201	0.75 (0.54–1.05)	0.01	0.65 (0.43–1.00)	0.05
Radiation	404 vs 180	1.02 (0.72–1.45)	0.90	1.08 (0.70–1.65)	0.74
Endocrine therapy, any	345 vs 239	0.74 (0.53–1.04)	0.08	0.84 (0.53–1.32)	0.44
Mutation location, OCCRs + BCCRs vs “Other”e	391 vs 193	1.58 (1.04–2.41)	0.03	1.26 (0.76–2.09)	0.38

^aAdjusted also for country, prophylactic mastectomy and unknown grade.

^bOestrogen-receptor positive up to 5 years after diagnosis vs oestrogen-receptor negative.

^cOestrogen-receptor positive 5 years or more after diagnosis vs oestrogen-receptor negative.

^dBefore or within 2 years from diagnosis.

^eOther locations than ovarian cancer cluster regions (OCCRs) or breast cancer cluster regions (BCCRs).